

# ForPatients

by Roche

Diffuse Large B-Cell Lymphoma (DLBCL) Chronic Lymphocytic Leukemia

## A study to look at how safe was it to give people with blood cancer (non-Hodgkin's lymphoma and chronic lymphocytic leukemia) – different doses of a study medicine (fenebrutinib)

**Trial Status**  
Completed

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT01991184 GO29089

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This clinical trial was done to study a new medicine (fenebrutinib) for the treatment of patients with blood cancer. This was a phase 1, dose-escalation study to find out which dose of fenebrutinib was safe and tolerable for people with B-cell non-Hodgkin's lymphoma (B-NHL) and chronic lymphocytic leukemia (B-CLL). Twenty-four people with B-NHL or B-CLL – that had come back (relapsed) or did not respond to medicine (refractory) – where the disease had gotten worse (progressed) even after getting available medicines – and for which no other effective medicine was available – took part in this study. The study took place at nine study centers in two countries – USA and Australia.

**Genentech, Inc. (Part of F. Hoffmann-La Roche Ltd., Switzerland)**  
Sponsor

**Phase 1**  
Phase

---

**NCT01991184 GO29089**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---